Shots:

• The approval is based on the results of P-II EMPOWER-CSCC-1 study and P-I study 1423 (two advanced CSCC expansion cohorts) assessing Libtayo in patients with mCSCC- locally advanced CSCC or Combined CSCC enrolling ≥163 candidates
• P-II EMPOWER-CSCC-1 study & P-I study 1423 Results: ORR (47%- 49%- 47%); CRR (5%- 0%- 4%); PRR (41%- 49%- 44%)- showing its safety and efficacy
• Libtayo is a fully human mAb targeting PD-1 receptor and approved for CSCC in the US with recommended dose 350 mg IV infusion over 30 min every three weeks

/ article | Ref: Sanofi | Image: Lung Disease News